By Catherine Shaffer A team of researchers at Thomas Jefferson University, Philadelphia, led by Carlo Croce, MD, has created a powerful tool for the characterization of microRNAs or miRNAs, the newest members of the growing family of genetically significant small RNAs.
By Mark Terry CTI Molecular Imaging Inc., Knoxville, Tenn., announced at the 2004 annual meeting of the Society of Nuclear Medicine held the week of June 20th in Philadelphia, that it has formed a separate company
By Catherine Shaffer If you travel east through Quebec on the Trans-Canada Highway, you'll pass through cities such as Rouyn-Noranda, Val d'Or, Montreal, Drummondville, and Montmagny. Signs by the roadside help you navigate (in two languages).
By Mark Terry In a plenary talk given May 18, 2004, before the Cambridge Healthtech Institute World Congress for Success, Robert Ruffolo, Jr., PhD, president, Wyeth Research, and senior vice president, Wyeth Pharmaceuticals, Collegeville, Pa., focused much of the blame for the industry's declining productivity on over-regulation.
By Catherine Shaffer A new study published in Cancer Cell zeros in on the transcriptional regulator TAL1 (or SCL) as a culprit in the most deadly form of T cell acute lymphoblastic leukemia (T-ALL), accounting for a significant minority of all cases. Patients with T-ALL induced by TAL1 activation
By Don Monroe A small-molecule treatment for breast cancer that targets the urokinase-type plasminogen activator (uPA) system has entered phase I clinical trials. The Fox Chase Cancer Center, Philadelphia
By Catherine Shaffer Merck Co. Inc., Whitehouse Station, N.J., is gambling on an old technology to overcome obstacles in delivering new DNA vaccines. The global pharmaceutical company has recently signed an agreement with Genetronics Biomedical Corp., San Diego, to license their MedPulser DNA Delivery System, an electroporation device.
Matrix metalloproteinases (MMPs) are a group of Zn2+ dependent endopeptidases involved in remodeling and degradation of the extracellular membrane (ECM).
Antioxidant Assay measures the overall antioxidant capacity within a given sample. It relies on the ability of antioxidants in the sample to inhibit the oxidation of ABTS® in comparison to Trolox, a water-soluble tocopherol analogue.
Malachite Green Lipid Phosphatase assays offer a non-radioactive alternative for measuring specific phosphatase activities. Seven phosphatase substrates are available.
Instant ELISA facilitates the quantitative detection of human TRANCE. TRANCE (or RANKL) is a member of the TNF superfamily that emerges as a key regulator of the immune system, of bone development, and of homeostasis.
An expanded SNP discovery service has been launched for pre-validated sequencing assays of kinases, genes implicated in many human diseases.
Proprietary recombinant proteins are ideal for use as positive controls in a variety of applications, including in vitro transcription assays, as EMSA controls in DNA-protein interaction studies, and as protein standards in ELISAs and Westerns.
New 450 kb probe detects alterations to the HER-2/ neu proto-oncogene (also called ERBB2), and is over-expressed in some breast, ovarian, prostate, and colorectal cancers, playing a possible role in tumor-cell proliferation, tumor invasion, and tumor metastasis.
Immunology line includes cytokine ELISA kits, cytokine ELISA construction kits, recombinant cytokines, growth factors, monoclonal and polyclonal antibodies, cytokines and CD markers, and matched antibody pairs. Custom immunological services are now available.